文献速递外周动脉疾病主动脉疾病颈动脉与弓上血管

抗血栓与降脂治疗与血管外科术后生存改善相关:一项挪威人群基础研究

Antithrombotic and Lipid Lowering Therapy is Associated With Improved Survival After Vascular Surgery: A Population Based Study From Norway.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-10-20

这项挪威人群基础回顾性队列研究纳入2015至2019年挪威血管外科登记中颈动脉狭窄、腹主动脉瘤和外周动脉疾病出院存活患者,分析降脂药联合抗血小板或抗凝治疗与长期生存的关联。结果显示,出院时使用推荐药物者生存更优,外周动脉疾病和腹主动脉瘤患者死亡风险显著降低。

要点

  • 出院时使用推荐药物与所有治疗组生存改善相关。
  • 外周动脉疾病患者生存获益最大,平均生存期4.33年 vs 3.70年。
  • 外周动脉疾病和腹主动脉瘤患者死亡风险显著降低,HR分别为0.58和0.57。

核心结论

  • 推荐药物与所有治疗组和男女两性生存改善相关,外周动脉疾病和腹主动脉瘤患者生存差异有统计学意义。
  • 外周动脉疾病患者改善最大,因此推荐二级预防在这些患者中尤为重要。

研究设计与样本

  • 挪威人群基础回顾性队列研究,纳入2015至2019年挪威血管外科登记中因颈动脉狭窄、腹主动脉瘤和动脉粥样硬化性下肢动脉疾病治疗且出院存活的患者。
  • 临床和用药信息来自登记,生存分析采用Kaplan-Meier法和多变量Cox回归模型,按治疗组、性别及是否接受推荐药物分层。

主要发现

  • 共纳入外周动脉疾病15810例、腹主动脉瘤4080例、颈动脉狭窄2194例。
  • 外周动脉疾病患者出院时使用推荐药物者平均生存期4.33年(95%CI 4.29-4.36),未使用者3.70年(95%CI 3.64-3.77),p<.001。
  • 腹主动脉瘤患者出院时使用推荐药物者平均生存期4.67年(95%CI 4.61-4.73),未使用者4.34年(95%CI 4.24-4.44),p<.001。
  • Cox回归显示外周动脉疾病患者出院时使用推荐药物者死亡率显著更低(HR 0.58;p<.001),腹主动脉瘤患者亦显著更低(HR 0.57;p<.001)。

关键数值与推荐

  • 推荐药物定义为降脂药(通常为他汀类)联合抗血小板药,或有时因合并症需要抗凝时使用抗凝药。
  • 外周动脉疾病患者出院时使用推荐药物者平均生存期4.33年(95%CI 4.29-4.36) vs 未使用者3.70年(95%CI 3.64-3.77),p<.001。
  • 腹主动脉瘤患者出院时使用推荐药物者平均生存期4.67年(95%CI 4.61-4.73) vs 未使用者4.34年(95%CI 4.24-4.44),p<.001。
  • 外周动脉疾病患者出院时使用推荐药物者死亡风险HR 0.58(p<.001),腹主动脉瘤患者HR 0.57(p<.001)。

临床怎么用

  • 作者认为,推荐二级预防在外周动脉疾病患者中尤为重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This population based retrospective cohort study aimed to investigate the association between combined treatment with lipid lowering drugs and antiplatelet or anticoagulation therapy and long term survival following vascular surgery in Norway. METHODS: The study included all patients who were registered for the treatment of carotid stenosis, abdominal aortic aneurysm (AAA), and atherosclerotic lower extremity arterial disease (LEAD) in the Norwegian Registry for Vascular Surgery between 2015 and 2019 and who were discharged alive. Clinical and medication details were retrieved from the register. Survival was assessed with Kaplan-Meier analysis and a multivariable Cox regression model. Stratification was according to treatment group, patient sex, and if patients received the recommended medications or not. Recommended medications were defined as lipid lowering drugs, usually statins, and antiplatelets, or sometimes anticoagulants, when comorbidity indicated anticoagulation therapy. RESULTS: In total, 15 810 patients had LEAD, 4 080 patients AAA, and 2 194 patients had carotid stenosis. In all treatment groups, survival was superior for patients who used the recommended medications upon discharge. The difference was greatest in patients with LEAD with mean survival periods of 4.33 (95% CI 4.29 - 4.36) and 3.7 (95% CI 3.64 - 3.77) years in patients discharged with and without the recommended medications, respectively (p < .001). The mean survival periods were 4.67 (95% CI 4.61 - 4.73) and 4.34 (95% CI 4.24 - 4.44) years in patients with AAA discharged with and without the recommended medications, respectively (p < .001). Cox regression analysis showed a statistically significantly lower mortality rate for patients discharged with the recommended medications for LEAD (HR 0.58; p < .001) and AAA (HR 0.57; p < .001). CONCLUSION: The recommended medications were associated with improved survival in all treatment groups and both sexes. The survival difference was statistically significant in patients with LEAD and AAA. Patients with LEAD had the greatest improvement; therefore, the recommended secondary prophylaxis is especially important in these patients.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Altreuther M, Seternes A, Saltnes T, et al. Antithrombotic and Lipid Lowering Therapy is Associated With Improved Survival After Vascular Surgery: A Population Based Study From Norway. Eur J Vasc Endovasc Surg. 2023. PMID: 37866794. doi:10.1016/j.ejvs.2023.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。